
|Articles|October 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 10
- Volume 16
- Issue 10
Merck to donate 3 million doses of Gardasil to poor countries
Merck to donate 3 million doses of Gardasil to poor countries
Advertisement
NEW YORKMerck & Co. has committed to donate at least 3 million doses of it human papillomavirus vaccine Gardasil over the next 5 years for use in demonstration projects in lowest income nations throughout the world. The company made the announcement at the Clinton Global Initiative 2007 meeting. "We are committing to the vaccination of 1 million females against cervical cancer," said Merck's Margaret McGlynn.
Articles in this issue
about 19 years ago
Bill aims to 'revitalize' FDA by adding powers and databasesabout 19 years ago
New myeloma trial results; two new studies initiatedabout 19 years ago
Neoadjuvant trastuzumab increases pCR ratesabout 19 years ago
Court rejects right of terminally ill to unproven drugsabout 19 years ago
Sorafenib improves overall survival in Asian HCC ptsabout 19 years ago
Skipping tam doses increases risk of deathabout 19 years ago
The SGR: The madness behind physician payment fee cutsabout 19 years ago
Dr. Pegram seeks new breast cancer challenges at Miamiabout 19 years ago
SearchMedica.com receives awardAdvertisement
Related to this article

Anne Chiang, MD, PhD, discusses how community practices can deliver bispecifics, monitor for CRS, and offer trials for patients with SCLC.

“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.

ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape
2
Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC
3
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
4
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
5

